Belite Bio (BLTE) CEO Lin Yu-Hsin sells 365 ADS in pre-set trading plan

Rhea-AI Filing Summary

BELITE BIO, INC director and Chief Executive Officer Lin Yu-Hsin reported selling a total of 365 American depositary shares of the company on 2026-08-12 in two open-market or private transactions at prices of $180.00 and $180.57 per share. Each American depositary share represents one ordinary share with a par value of US$0.0001. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 12/23/2025.

Insider Trade Summary 10b5-1

Net Seller: 365 shares

Net Sell 2 txns

Insider Lin Yu-Hsin

Role Chief Executive Officer

Sold 365 shs ($66K)

Type	Security	Shares	Price	Value
Sale	American depositary share F1, F2	142	$180.00	$26K
Sale	American depositary share F1, F2	223	$180.57	$40K

Holdings After Transaction: American depositary share — 170,569 shares (Direct)

Footnotes (2)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025.

Key Figures

Shares sold: 365 American depositary shares First transaction size: 142 American depositary shares First transaction price: $180.0000 per share +4 more

7 metrics

Shares sold 365 American depositary shares Total non-derivative shares sold by CEO on 2026-08-12

First transaction size 142 American depositary shares Portion of total shares sold at $180.0000 per share

First transaction price $180.0000 per share Sale price for 142 American depositary shares on 2026-08-12

Second transaction size 223 American depositary shares Portion of total shares sold at $180.5700 per share

Second transaction price $180.5700 per share Sale price for 223 American depositary shares on 2026-08-12

Par value per ordinary share US$0.0001 per share Par value of each ordinary share represented by one ADS

10b5-1 plan adoption date 12/23/2025 Adoption date of trading plan governing the reported sales

Key Terms

American depositary share, Rule 10b5-1 trading plan, par value, open market or private transaction

4 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

par value financial

"one ordinary share, par value US$0.0001 per share, of the issuer"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

What insider transactions did BELITE BIO (BLTE) report for Lin Yu-Hsin?

BELITE BIO CEO Lin Yu-Hsin reported selling 365 American depositary shares on 2026-08-12 in two open-market or private transactions, at per-share prices of $180.00 and $180.57, under a pre-established Rule 10b5-1 trading plan.

How many BELITE BIO (BLTE) shares did the CEO sell and at what prices?

The CEO sold 365 American depositary shares of BELITE BIO, with 142 shares sold at $180.00 per share and 223 shares sold at $180.57 per share in transactions dated 2026-08-12.

Were the BELITE BIO (BLTE) CEO’s share sales made under a Rule 10b5-1 plan?

Yes, the filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025, indicating the transactions followed a pre-arranged trading program.

What does each BELITE BIO (BLTE) American depositary share represent?

Each BELITE BIO American depositary share represents one ordinary share of the issuer with a par value of US$0.0001 per share, providing indirect ownership of the company’s underlying ordinary shares.

Does the Form 4 for BELITE BIO (BLTE) show the CEO’s remaining holdings?

The Form 4 reports the 365 American depositary shares sold but does not state a specific total for shares held following the transactions, so only the reported sale amounts are disclosed in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 06:10 AM Accepted by SEC EDGAR 08/14/2026 - 06:10 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Yu-Hsin

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	08/12/2026		S(2)		142	D	$180	170,792	D
American depositary share(1)	08/12/2026		S(2)		223	D	$180.57	170,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025.

	/s/ Lin Yu-Hsin	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)